

Mehul Dhorda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6151745/publications.pdf>

Version: 2024-02-01

69
papers

6,476
citations

159585

30
h-index

110387

64
g-index

77
all docs

77
docs citations

77
times ranked

5395
citing authors

#	ARTICLE	IF	CITATIONS
1	Mapping genetic markers of artemisinin resistance in <i>Plasmodium falciparum</i> malaria in Asia: a systematic review and spatiotemporal analysis. <i>Lancet Microbe</i> , The, 2022, 3, e184-e192.	7.3	16
2	Triple therapy with artemether+lumefantrine plus amodiaquine versus artemether+lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 867-878.	9.1	27
3	Artemisinin resistance in the malaria parasite, <i>Plasmodium falciparum</i> , originates from its initial transcriptional response. <i>Communications Biology</i> , 2022, 5, 274.	4.4	33
4	Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 804470.	3.9	1
5	Optimizing bulk segregant analysis of drug resistance using <i>Plasmodium falciparum</i> genetic crosses conducted in humanized mice. <i>IScience</i> , 2022, 25, 104095.	4.1	8
6	Field evaluation of the diagnostic performance of EasyScan GO: a digital malaria microscopy device based on machine-learning. <i>Malaria Journal</i> , 2022, 21, 122.	2.3	15
7	Triple Artemisinin-Based Combination Therapies for Malaria – A New Paradigm?. <i>Trends in Parasitology</i> , 2021, 37, 15-24.	3.3	67
8	Performance of a fully-automated system on a WHO malaria microscopy evaluation slide set. <i>Malaria Journal</i> , 2021, 20, 110.	2.3	21
9	Deploying triple artemisinin-based combination therapy (TACT) for malaria treatment in Africa: ethical and practical considerations. <i>Malaria Journal</i> , 2021, 20, 119.	2.3	17
10	A Systematic Literature Review of Microscopy Methods Reported in Malaria Clinical Trials. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 836-841.	1.4	4
11	Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol.. <i>Wellcome Open Research</i> , 2021, 6, 75.	1.8	4
12	Artemisinin and multidrug-resistant <i>Plasmodium falciparum</i> – a threat for malaria control and elimination. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 432-439.	3.1	51
13	Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination. <i>ELife</i> , 2021, 10, .	6.0	53
14	To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?. <i>PLoS ONE</i> , 2021, 16, e0256567.	2.5	7
15	Evolution of Multidrug Resistance in <i>Plasmodium falciparum</i> : a Longitudinal Study of Genetic Resistance Markers in the Greater Mekong Subregion. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0112121.	3.2	21
16	Arterolane+piperazine+mefloquine versus arterolane+piperazine and artemether+lumefantrine in the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1395-1406.	9.1	20
17	The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of <i>Plasmodium vivax</i> infections: a randomized, controlled trial in Lao PDR. <i>Malaria Journal</i> , 2020, 19, 4.	2.3	4
18	A comprehensive RNA handling and transcriptomics guide for high-throughput processing of <i>Plasmodium</i> blood-stage samples. <i>Malaria Journal</i> , 2020, 19, 363.	2.3	19

#	ARTICLE	IF	CITATIONS
19	Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1470-1480.	9.1	94
20	Towards harmonization of microscopy methods for malaria clinical research studies. <i>Malaria Journal</i> , 2020, 19, 324.	2.3	13
21	Highlights 2020: framing health stories. <i>Lancet</i> , The, 2020, 396, 1957-1971.	13.7	0
22	Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated <i>Plasmodium falciparum</i> malaria: a multicentre, open-label, randomised clinical trial. <i>Lancet</i> , The, 2020, 395, 1345-1360.	13.7	182
23	Mass drug administrations with dihydroartemisinin-piperazine and single low dose primaquine to eliminate <i>Plasmodium falciparum</i> have only a transient impact on <i>Plasmodium vivax</i> : Findings from randomised controlled trials. <i>PLoS ONE</i> , 2020, 15, e0228190.	2.5	6
24	Short-course primaquine for the radical cure of <i>Plasmodium vivax</i> malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. <i>Lancet</i> , The, 2019, 394, 929-938.	13.7	106
25	Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 943-951.	9.1	219
26	Determinants of dihydroartemisinin-piperazine treatment failure in <i>Plasmodium falciparum</i> malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 952-961.	9.1	252
27	Artemisinin Resistance and Stage Dependency of Parasite Clearance in <i>Falciparum</i> Malaria. <i>Journal of Infectious Diseases</i> , 2019, 219, 1483-1489.	4.0	25
28	Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives. <i>Journal of Infectious Diseases</i> , 2019, 220, 1178-1187.	4.0	21
29	Polymorphisms in <i>Pvkelch12</i> and gene amplification of <i>Pvplasmepsin4</i> in <i>Plasmodium vivax</i> from Thailand, Lao PDR and Cambodia. <i>Malaria Journal</i> , 2019, 18, 114.	2.3	4
30	The impact of targeted malaria elimination with mass drug administrations on <i>falciparum</i> malaria in Southeast Asia: A cluster randomised trial. <i>PLoS Medicine</i> , 2019, 16, e1002745.	8.4	105
31	Fully-automated patient-level malaria assessment on field-prepared thin blood film microscopy images. , 2019, , .		5
32	Mapping imported malaria in Bangladesh using parasite genetic and human mobility data. <i>ELife</i> , 2019, 8, .	6.0	78
33	An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1737-1749.	3.0	47
34	Plasmepsin II copy number accounts for bimodal piperazine resistance among Cambodian <i>Plasmodium falciparum</i> . <i>Nature Communications</i> , 2018, 9, 1769.	12.8	85
35	Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on <i>Plasmodium falciparum</i> malaria in Eastern Myanmar: an observational study of a regional elimination programme. <i>Lancet</i> , The, 2018, 391, 1916-1926.	13.7	131
36	A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant <i>Falciparum</i> Malaria in Cambodian Villages. <i>Clinical Infectious Diseases</i> , 2018, 67, 817-826.	5.8	48

#	ARTICLE	IF	CITATIONS
37	Effectiveness and safety of 3 and 5-day courses of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar. <i>Malaria Journal</i> , 2018, 17, 258.	2.3	27
38	A novel field-based molecular assay to detect validated artemisinin-resistant k13 mutants. <i>Malaria Journal</i> , 2018, 17, 175.	2.3	4
39	The spread of artemisinin-resistant <i>Plasmodium falciparum</i> in the Greater Mekong subregion: a molecular epidemiology observational study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 491-497.	9.1	371
40	Artemisinin resistance without pfcy5 mutations in <i>Plasmodium falciparum</i> isolates from Cambodia. <i>Malaria Journal</i> , 2017, 16, 195.	2.3	99
41	Host immunity to <i>Plasmodium falciparum</i> and the assessment of emerging artemisinin resistance in a multinational cohort. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3515-3520.	7.1	78
42	Submicroscopic <i>Plasmodium</i> prevalence in relation to malaria incidence in 20 villages in western Cambodia. <i>Malaria Journal</i> , 2017, 16, 56.	2.3	40
43	Computer-Automated Malaria Diagnosis and Quantitation Using Convolutional Neural Networks. , 2017, , .		52
44	Defining the next generation of <i>Plasmodium vivax</i> diagnostic tests for control and elimination: Target product profiles. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005516.	3.0	24
45	Abundance of megalin and Dab2 is reduced in syncytiotrophoblast during placental malaria, which may contribute to low birth weight. <i>Scientific Reports</i> , 2016, 6, 24508.	3.3	11
46	Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. <i>Malaria Journal</i> , 2016, 15, 185.	2.3	43
47	Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant <i>Plasmodium falciparum</i> distributions in Southeast Asia. <i>International Journal of Health Geographics</i> , 2016, 15, 37.	2.5	13
48	Persistent <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> infections in a western Cambodian population: implications for prevention, treatment and elimination strategies. <i>Malaria Journal</i> , 2016, 15, 181.	2.3	54
49	History of malaria treatment as a predictor of subsequent subclinical parasitaemia: a cross-sectional survey and malaria case records from three villages in Pailin, western Cambodia. <i>Malaria Journal</i> , 2016, 15, 240.	2.3	21
50	Numerical Distributions of Parasite Densities During Asymptomatic Malaria. <i>Journal of Infectious Diseases</i> , 2016, 213, 1322-1329.	4.0	108
51	Association between Subclinical Malaria Infection and Inflammatory Host Response in a Pre-Elimination Setting. <i>PLoS ONE</i> , 2016, 11, e0158656.	2.5	13
52	The epidemiology of subclinical malaria infections in South-East Asia: findings from cross-sectional surveys in Thailand-Myanmar border areas, Cambodia, and Vietnam. <i>Malaria Journal</i> , 2015, 14, 381.	2.3	163
53	Genetic architecture of artemisinin-resistant <i>Plasmodium falciparum</i> . <i>Nature Genetics</i> , 2015, 47, 226-234.	21.4	515
54	Spread of artemisinin-resistant <i>Plasmodium falciparum</i> in Myanmar: a cross-sectional survey of the K13 molecular marker. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 415-421.	9.1	363

#	ARTICLE	IF	CITATIONS
55	Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. <i>Science</i> , 2015, 347, 431-435.	12.6	362
56	Spread of Artemisinin Resistance in <i>Plasmodium falciparum</i> Malaria. <i>New England Journal of Medicine</i> , 2014, 371, 411-423.	27.0	1,753
57	Polymorphisms in <i>Plasmodium falciparum</i> Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for <i>P. falciparum</i> Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 833-843.	1.4	204
58	Population pharmacokinetics of quinine in pregnant women with uncomplicated <i>Plasmodium falciparum</i> malaria in Uganda. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3033-3040.	3.0	22
59	Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial. <i>Malaria Journal</i> , 2013, 12, 251.	2.3	30
60	Pharmacokinetic Properties of Artemether, Dihydroartemisinin, Lumefantrine, and Quinine in Pregnant Women with Uncomplicated <i>Plasmodium falciparum</i> Malaria in Uganda. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5096-5103.	3.2	41
61	Performance of a Histidine-Rich Protein 2 Rapid Diagnostic Test, Paracheck Pf [®] , for Detection of Malaria Infections in Ugandan Pregnant Women. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 86, 93-95.	1.4	24
62	Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated <i>Plasmodium falciparum</i> malaria in Uganda. <i>Malaria Journal</i> , 2012, 11, 293.	2.3	38
63	Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood <i>Plasmodium falciparum</i> malaria in Democratic Republic of Congo: a randomized non-inferiority trial. <i>Malaria Journal</i> , 2012, 11, 174.	2.3	28
64	Artemether-lumefantrine to treat malaria in pregnancy is associated with reduced placental haemozoin deposition compared to quinine in a randomized controlled trial. <i>Malaria Journal</i> , 2012, 11, 150.	2.3	17
65	Transmission of <i>Plasmodium vivax</i> in South-Western Uganda: Report of Three Cases in Pregnant Women. <i>PLoS ONE</i> , 2011, 6, e19801.	2.5	17
66	Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated <i>Plasmodium falciparum</i> malaria: an open-label, randomised, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 762-769.	9.1	96
67	Prevalence Study of Yaws in the Democratic Republic of Congo Using the Lot Quality Assurance Sampling Method. <i>PLoS ONE</i> , 2009, 4, e6338.	2.5	24
68	Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV). <i>Wellcome Open Research</i> , 0, 5, 241.	1.8	5
69	Comparison of antibody responses and parasite clearance in artemisinin therapeutic efficacy studies in Democratic Republic of Congo and Asia. <i>Journal of Infectious Diseases</i> , 0, , ,	4.0	1